ARMYDA研究课件（PPT 5页）.pptVIP

Atorvastatin for Reduction of Myocardial Damage During Angioplasty ARMYDA Trial ARMYDA Trial ARMYDA Trial Among patients undergoing elective PCI irrespective of baseline lipid levels, pre-treatment with atorvastatin was associated with a reduction in markers of myocardial injury post-procedure LIPS trial showed reduction in long-term cardiac events associated with statin use in patients undergoing PCI; however, statin therapy was initiated post-procedure and effect on early myocardial injury was not evaluated Mechanism of action for reduction of myocardial injury unclear but may be related to anti-inflammatory effect of statins Further evaluation warranted Pasceri V, et al Circulation 2004;110:674-8 ARMYDA Trial Atorvastatin 40 mg/d n=76 Primary Endpoint: Occurrence of MI, defined as a post-procedural increase of CK-MB 2 times above ULN ARMYDA Trial Circulation 2004;110:674-8 153 patients scheduled for elective PCI irrespective of baseline lipid levels Randomized, double-blind Placebo n=77 Treatment for 7 days Primary endpoint of post-procedure MI (CKMB2x ULN) ↓ in atorvastatin group vs placebo (Figure) Presence of markers 1x ULN also ↓ in atorvastatin arm: CKMB 12% vs 35%, p=0.001; troponin I 20% vs 48% p=0.0004; myoglobin 22% vs 51%, p=0.0005 Circulation 2004;110:674-8 Post-procedure MI (2x ULN) p = 0.025 Peak CK-MB p = 0.007 Peak Troponin I p = 0.0008 Circulation 2004;110:674-8 ng/mL ng/mL